Future Horizons: Nanotechnology and Gene Therapy

Review Paper | 2025 | Volume 1 | Issue 1 | Page 17-25

Dr. Amrish Singh, Lecturer, Department of Genetics, SNS College, Nawada

Abstract

Future Horizons: Nanotechnology and Gene Therapy.

Download • 470KB

As we approach the 2030 threshold, the paradigm of interventional cardiology is shifting from mechanical restoration to biological rejuvenation. The final frontier of "NextGen" cardiology lies in the integration of Nanotechnology and Gene Therapy, moving beyond the macro-scale of stents and valves into the sub-cellular environment. This chapter explores the visionary horizon where the "Cath Lab" evolves into a molecular suite capable of permanent disease modification rather than temporary repair. We examine the emerging methodology of Nanoparticle-Mediated Drug Delivery, which allows for the high-affinity targeting of "vulnerable plaques" using biomimetic carriers that release anti-inflammatory payloads only in the presence of specific enzymatic triggers. A primary focus is placed on the revolutionary potential of CRISPR-Cas9 Gene Editing for the "one-and-done" treatment of familial hypercholesterolemia and transthyretin amyloidosis (ATTR). By analyzing the 2025–2026 early-phase results of the VERVE and HEART-EDIT trials, this chapter discusses the transition of the cardiologist from a "plumber" to a "genetic engineer." Furthermore, we explore the development of Injectable Hydrogels for myocardial regeneration following a massive infarction, aiming to reverse heart failure at its source. By synthesizing these cutting-edge innovations, the chapter concludes that the future of cardiology is no longer about managing chronic illness, but about the curative potential of molecular and atomic precision.